Tara Noonan, APRN
Family · Hamden, CTNPI 1447720644
Payments from drug & device makers
Across 283 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$646
- AbbVie$557
- GSK$549
- Merck$433
- Lilly USA, LLC$367
- Pfizer$347
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,287100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $646 |
| AbbVie | 39 | $557 |
| GSK | 29 | $549 |
| Merck | 21 | $433 |
| Lilly USA, LLC | 18 | $367 |
| Pfizer | 20 | $347 |
| Novo Nordisk | 15 | $298 |
| Inspire Medical Systems, Inc. | 7 | $212 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $206 |
| Amgen | 10 | $187 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $184 |
| Boehringer Ingelheim | 9 | $169 |
| Sunovion Pharmaceuticals Inc. | 15 | $154 |
| ANI Pharmaceuticals, Inc. | 6 | $144 |
| Sumitomo Pharma America, Inc. | 6 | $131 |
| Valinor Pharma, LLC | 7 | $128 |
| Collegium Pharmaceutical, Inc. | 6 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Exact Sciences | 3 | $61 |
| Neurocrine Biosciences, Inc. | 2 | $57 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Johnson & Johnson | 2 | $38 |
| Scilex Pharmaceuticals Inc. | 2 | $30 |
| Ironwood Pharmaceuticals, Inc | 1 | $27 |
| Bayer | 1 | $26 |
| Biogen | 1 | $25 |
| Neurelis, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Qiagen, LLC | 1 | $12 |
How this compares
$5,287 in reported general payments places this provider in the 90th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 47 | $44,115 |
| TrulicityDulaglutide | 19 | $28,367 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $22,948 |
| EliquisApixaban | 27 | $20,977 |
| GemtesaVibegron | 22 | $17,357 |
| MounjaroTirzepatide | 12 | $13,286 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,874 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,576 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $2,172 |
| Ventolin HfaAlbuterol Sulfate | 14 | $1,559 |
| Rosuvastatin Calcium | 101 | $1,067 |
| Atorvastatin Calcium | 121 | $1,034 |
| Gabapentin | 38 | $836 |
| Duloxetine Hcl | 21 | $754 |
| Metformin Hcl ErMetformin Hcl | 32 | $709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $646 | $46,69158 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $367 | $41,65431 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $549 | $32,82232 claims |
| PfizerEliquis | $347 | $20,97727 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $131 | $17,35722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,596 family providers in Connecticut.
Other family in Hamden
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
- Ralph HirschfeldPutnam$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.